• Je něco špatně v tomto záznamu ?

Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC

H. Hebart, M. Kiehl, J. Tomasek, T. Csoszi, R. Koukakis, G. Kafatos, A. Kuhn, K. Bjorklof, G. Demonty, T. Buchler,

. 2019 ; 36 (3) : 670-683. [pub] 20190128

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, pozorovací studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006618

INTRODUCTION: This study aimed to better understand panitumumab use in real-life clinical practice in first- and second-line treatment of metastatic colorectal cancer in five European countries. METHODS: This is a combined analysis of two observational, non-interventional prospective cohort studies, one of which was conducted in Germany and France, the other in Bulgaria, Czech Republic, and Hungary. The studies observed patients with wild-type [Kirsten] rat sarcoma viral oncogene homolog ([K]RAS/RAS) metastatic colorectal cancer (mCRC), who had been treated with panitumumab in combination with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in the first line or with panitumumab combined with fluorouracil, leucovorin, and irinotecan (FOLFIRI) in the second line following fluoropyrimidine-based chemotherapy. The planned duration of observation was 12 months from the first dose of panitumumab. RESULTS: A total of 332 patients treated with panitumumab + FOLFOX in the first line and 94 patients treated with panitumumab + FOLFIRI in the second line were analyzed. The median number of panitumumab infusions was 10.0 in first-line FOLFOX patients and 11.5 in second-line FOLFIRI patients; the median duration of panitumumab exposure was 5.7 and 6.9 months, respectively. The unadjusted overall response rate (complete or partial response) in patients with available post-baseline response assessment (n = 290) was 51.7% in first-line FOLFOX and 44.9% in second-line FOLFIRI patients. In the first-line setting, resectability was achieved in 9.3%. Reported hospitalizations were mostly cancer-related visits such as scheduled anticancer treatment administrations, tumor assessment visits, or interventions. The majority of adverse drug reactions were skin disorders, with 75.3% in first-line FOLFOX patients and 72.3% in second-line FOLFIRI patients. CONCLUSION: Overall, the study results show that treatment patterns, clinical efficacy, and the safety profile of panitumumab in routine clinical practice were comparable to those in randomized controlled trials. The relatively low skin toxicity rate could be attributed to increasing experience in managing panitumumab-associated rash and some degree of underreporting. FUNDING: Amgen.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006618
003      
CZ-PrNML
005      
20200526143624.0
007      
ta
008      
200511s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12325-019-0874-6 $2 doi
035    __
$a (PubMed)30689133
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hebart, Holger $u Department of Internal Medicine, Stauferklinikum Schwäbisch Gmünd, Mutlangen, Germany. Holger.Hebart@kliniken-ostalb.de.
245    10
$a Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC / $c H. Hebart, M. Kiehl, J. Tomasek, T. Csoszi, R. Koukakis, G. Kafatos, A. Kuhn, K. Bjorklof, G. Demonty, T. Buchler,
520    9_
$a INTRODUCTION: This study aimed to better understand panitumumab use in real-life clinical practice in first- and second-line treatment of metastatic colorectal cancer in five European countries. METHODS: This is a combined analysis of two observational, non-interventional prospective cohort studies, one of which was conducted in Germany and France, the other in Bulgaria, Czech Republic, and Hungary. The studies observed patients with wild-type [Kirsten] rat sarcoma viral oncogene homolog ([K]RAS/RAS) metastatic colorectal cancer (mCRC), who had been treated with panitumumab in combination with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in the first line or with panitumumab combined with fluorouracil, leucovorin, and irinotecan (FOLFIRI) in the second line following fluoropyrimidine-based chemotherapy. The planned duration of observation was 12 months from the first dose of panitumumab. RESULTS: A total of 332 patients treated with panitumumab + FOLFOX in the first line and 94 patients treated with panitumumab + FOLFIRI in the second line were analyzed. The median number of panitumumab infusions was 10.0 in first-line FOLFOX patients and 11.5 in second-line FOLFIRI patients; the median duration of panitumumab exposure was 5.7 and 6.9 months, respectively. The unadjusted overall response rate (complete or partial response) in patients with available post-baseline response assessment (n = 290) was 51.7% in first-line FOLFOX and 44.9% in second-line FOLFIRI patients. In the first-line setting, resectability was achieved in 9.3%. Reported hospitalizations were mostly cancer-related visits such as scheduled anticancer treatment administrations, tumor assessment visits, or interventions. The majority of adverse drug reactions were skin disorders, with 75.3% in first-line FOLFOX patients and 72.3% in second-line FOLFIRI patients. CONCLUSION: Overall, the study results show that treatment patterns, clinical efficacy, and the safety profile of panitumumab in routine clinical practice were comparable to those in randomized controlled trials. The relatively low skin toxicity rate could be attributed to increasing experience in managing panitumumab-associated rash and some degree of underreporting. FUNDING: Amgen.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a kamptothecin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $x terapeutické užití $7 D002166
650    _2
$a kohortové studie $7 D015331
650    _2
$a kolorektální nádory $x farmakoterapie $x patologie $7 D015179
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fluoruracil $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D005472
650    _2
$a lidé $7 D006801
650    _2
$a leukovorin $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D002955
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a organoplatinové sloučeniny $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D009944
650    _2
$a panitumumab $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000077544
650    _2
$a prospektivní studie $7 D011446
650    _2
$a ras proteiny $x biosyntéza $7 D018631
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kiehl, Michael $u Medical Clinic I, Klinikum Frankfurt (Oder) GmbH, Frankfurt (Oder), Germany.
700    1_
$a Tomasek, Jiri $u Clinic of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Csoszi, Tibor $u Oncology Department, Hetenyi G. County Hospital, Szolnok, Hungary.
700    1_
$a Koukakis, Reija $u Department of Biostatistics, Amgen Ltd, Uxbridge, UK.
700    1_
$a Kafatos, George $u Center for Observational Research, Amgen Ltd, Uxbridge, UK.
700    1_
$a Kuhn, Anja $u Research and Development, Amgen GmbH, Munich, Germany.
700    1_
$a Bjorklof, Katja $u EU Medical Affairs, Amgen (Europe) GmbH, Rotkreuz, Switzerland.
700    1_
$a Demonty, Gaston $u Medical Development, Amgen, Brussels, Belgium.
700    1_
$a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.
773    0_
$w MED00179771 $t Advances in therapy $x 1865-8652 $g Roč. 36, č. 3 (2019), s. 670-683
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30689133 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200526143620 $b ABA008
999    __
$a ok $b bmc $g 1525476 $s 1096674
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 36 $c 3 $d 670-683 $e 20190128 $i 1865-8652 $m Advances in therapy $n Adv Ther $x MED00179771
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

    Možnosti archivace